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Objectives The aim of this study was to examine the effects of sarcoplasmic reticulum Ca2 ATPase (SERCA2a) gene trans-
fer in a swine heart failure (HF) model.
Background Reduced expression and activity of SERCA2a have been documented in HF. Prior studies have reported the ben-
eficial effects of short-term SERCA2a overexpression in rodent models. However, the effects of long-term expres-
sion of SERCA2a in pre-clinical large animal models are not known.
Methods Yorkshire-Landrace pigs were used (n  16) to create volume overload by percutaneously severing chordae
tendinae of the mitral apparatus with a bioptome to induce mitral regurgitation. At 2 months, pigs underwent
intracoronary delivery of either recombinant adeno-associated virus type 1 (rAAV1) carrying SERCA2a under a
cytomegalovirus promoter (rAAV1.SERCA2a) (n  10; group 1) or saline (n  6; group 2).
Results At 2 months, study animals were found to be in a compensated state of volume-overload HF (increased left ven-
tricular internal diastolic and systolic diameters [LVIDd and LVIDs]). At 4 months, gene transfer resulted in: 1)
positive left ventricular (LV) inotropic effects (adjusted peak left ventricular pressure rate of rise (dP/dt)max/P,
21.2  3.2 s1 group 1 vs. 15.5  3.0 s1 group 2; p  0.01); 2) improvement in LV remodeling (% change in
LVIDs 3.0  10% vs. 15  11%, respectively; p  0.01). At follow-up, brain natriuretic peptide levels re-
mained stable in group 1 after gene transfer, in contrast to rising levels in group 2. Further, cardiac SERCA2a
expression was significantly decreased in group 2 whereas in group 1 it was restored to normal levels. There
was no histopathological evidence of acute myocardial inflammation or necrosis.
Conclusions Using a large-animal, volume-overload model of HF, we report that long-term overexpression of SERCA2a by
in vivo rAAV1-mediated intracoronary gene transfer preserved systolic function, potentially prevented diastolic
dysfunction, and improved ventricular remodeling. (J Am Coll Cardiol 2008;51:1112–9) © 2008 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.12.0143
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March 18, 2008:1112–9 SERCA2a Gene Transfer in HFng to cardiomyocytes in the setting of chronic cardiac
ysfunction.
At the cellular level, HF is characterized by disturbances in
xcitation-contraction coupling (3,4). Alterations in calcium
Ca2) handling lead to impaired efflux of intracellular Ca2
ith defects in sarcoplasmic reticulum Ca2 loading and
elease. The pivotal role of the sarcoplasmic reticulum Ca2
TPase (SERCA2a) pump in Ca2 homeostasis has been
escribed, with reports of consistently decreased levels of
ERCA2a protein expression and activity in the failing
uman heart (5–7). Prior reports have shown that targeting
ERCA2a by gene transfer is feasible and represents a novel
herapeutic modality to improve diastolic and systolic dis-
urbances in HF (8–10).
Short-term expression, low efficiency, and immune re-
ponse elicited by current vectors has mitigated the thera-
eutic applicability of gene transfer (11). Adeno-associated
iruses (AAVs) have emerged as promising viral vectors
ue to more efficient uptake and stable, long-term ex-
ression of transferred genes (12). Moreover, the AAV1
erotype may be ideal for targeting the heart due to its
ropism for muscle tissues. Using a swine model of
olume-overload HF, we investigated the impact of
ERCA2a overexpression by AAV1 gene transfer.
erein, we show that the latter can lead to long-term
ncreases in SERCA2a tissue expression with both struc-
ural and functional cardiac improvement.
ethods
nimal care and all procedures were approved by local
nstitutional committees and were performed in accordance
ith the “Principles of Laboratory Animal Care by the
ational Society for Medical Research and the Guide for
he Care and Use of Laboratory Animals” (NIH Publication
o. 86-23, revised 1985).
olume-overload HF model creation. Yorkshire-
andrace swine (n  26, 33.5  1.8 kg) underwent the
rocedure to induce volume-overload HF. All study animals
ere sedated with telazol 6.0 mg/kg intramuscularly and
echanically ventilated with isoflurane 0.5% to 2% and
xygen. As previously reported (13), mitral regurgitation
MR) was created by inserting of an 8-F sheath into the
nternal carotid artery then under fluoroscopic guidance, a
ioptome (BIOPAL 7, Cordis Corp., Miami, Florida) was
ositioned in the left ventricle (LV) to rupture the chordae
endinae of the mitral valve apparatus. Serial hemodynamic
ere obtained with a high-fidelity, pressure transducer
atheter (Millar Instruments Inc., Houston, Texas). Severe
R at creation was confirmed angiographically (contrast
ye reflux into the pulmonary veins) and hemodynamically
increased LV end-diastolic pressure 16 mm Hg). Subse-
uently, study animals were allowed to recover and treated
ith daily oral furosemide (20 mg) and nitroglycerin (2 mg). lecombinant AAV1 carrying
ERCA2a (rAAV1.SERCA2a)
ector construction. Vector
roduction, harvest, purification,
nd testing were done as previ-
usly described (14). The
AAV1.SERCA2a vector used in
his study contains an AAV sero-
ype 1 viral capsid and a single-
tranded 4.5 kb DNA contain-
ng the human SERCA2a cDNA
riven by a CMV immediate-early
romoter/enhancer, a hybrid in-
ron, and a bovine growth hor-
one poly-adenylation signal, all
anked by 145 nt AAV2 inverted
erminal repeat sequences neces-
ary for replication and packaging
f the vector DNA in the capsid.
he vector was manufactured us-
ng standard calcium phosphate
ransfection methods in adherent
93 cells. Three plasmids were
sed, 1 containing helper func-
ions from adenovirus, 1 contain-
ng the AAV rep2 and cap1 genes,
nd the third containing the vector
enome. Final vector preparations
ere more than 95% pure as
udged by SDS-PAGE (Invitrogen, Carlsbad, California).
ector delivery. At 2 months, swine underwent intra-
oronary injection of either rAAV1.SERCA2a or saline. On
he day of injection, the virus was kept on ice after thaw-
ng. Subsequently, 1012 DNAse resistant particles of
AAV1.SERCA2a solution or a similar volume of saline was
iluted in buffer (130 mM NaCl, 20 mM HEPES, pH 7.4, 1
M MgCl2) (total volume of 10 ml). The mixture was then
ixed with 10 ml of autologous whole blood in preparation for
njection. A 7-F femoral artery sheath was placed and a
oronary guiding catheter was then selectively engaged into the
oronary artery ostium. After confirming catheter positioning
y coronary angiogram, either rAAV1.SERCA2a or saline was
elivered via a standard injection pump over 10 min.
ardiac parameters measurements. All parameters were
ollected at baseline (pre-MR creation), at 2 months (pre-
irus/saline injection) and at 4 months (sacrifice). The
verage of at least 3 consecutive cardiac cycles was used for
ach measurement.
A 6-F Millar MIKRO-TIP catheter (Millar Instruments
nc., Houston, Texas) positioned within the LV cavity was
sed to collect the following parameters: systolic pressure,
V end-diastolic pressure, peak LV pressure rate of rise
dP/dt)max and decline (dP/dt)min and Tau value (time
onstant of isovolumic relaxation); (dP/dt)max/P was calcu-
Abbreviations
and Acronyms
BNP  brain natriuretic
peptide
CK  creatine kinase
dP/dt  peak left
ventricular pressure rate
HF  heart failure
LV  left
ventricle/ventricular
LVEF  left ventricular
ejection fraction
LVIDd  left ventricular
internal diastolic diameter
LVIDs  left ventricular
internal systolic diameter
MR  mitral valve
regurgitation
rAAV1  recombinant
adeno-associated virus
type 1
RT-PCR  reverse
transcription polymerase
chain reaction
SERCA2a  sarcoplasmic
reticulum Ca2 ATPase
Tau  time constant of
isovolumic relaxationated as (dP/dt)max/(systolic  end-diastolic pressure).
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SERCA2a Gene Transfer in HF March 18, 2008:1112–9Transthoracic echocardiograms were performed under
imilar conditions (i.e., while study animals were mechani-
ally ventilated with isoflurane 0.5% to 2% with breath
olds during image acquisition) using the GE Vivid 7 cardio-
ascular ultrasound system (GE Medical Systems, Milwaukee,
isconsin) with a 3-MHz transducer. Serial echocardio-
raphic data were collected in a blinded fashion. The Teich-
olz method was employed to calculate LV volumes and
jection fraction (LVEF) (15). The parasternal long-axis view
as used to measure left ventricular diameters at end-diastole
LVIDd) and end-systole (LVIDs). Mitral regurgitation vol-
me was measured using the PISA method (16).
issue and blood samples. At study completion (4 months),
ntracoronary cardioplegic solution (Plegisol, Hospira Inc.,
ake Forest, Illinois) was used to perform humane eutha-
asia. Tissue samples from various organs (heart, brain,
keletal muscle, liver, adrenal glands, kidneys, lymph nodes,
nd ovaries) were placed in 10% formalin solution for
istological assessment. Tissues collected for Western blot
nd enzymatic analysis were snap-frozen with liquid nitro-
en. Serial blood samples were collected for brain natriuretic
eptide (BNP) measurements.
mmunoblotting. The microsomal fraction was prepared
rom snap-frozen swine heart (5 to 10 g of heart muscle),
ulverized in liquid nitrogen, and homogenized in a buffer
olution containing 5 mM Tris-HCl pH 7.4, 2 mM
DTA, and 8.5% sucrose with a Potter homogenizer. The
omogenate was centrifuged at 1,000  g for 10 min. The
upernatant was then centrifuged for 15 min at 9,000  g,
he resultant supernatant was spun twice for 15 min at
0,000  g. Sarcoplasmic reticulum vesicles present in this
atter 20,000  g supernatant were pelleted by a 1-h
10,000  g spin. The pellet was resuspended in 500 l of
he homogenization buffer. All centrifugations were per-
ormed at 0 to 4°C. Protein samples were prepared from
solated swine microsomal fractions, matched for protein
oncentration (using the Bradford method), and separated
y SDS-PAGE and transferred onto nitrocellulose mem-
ranes. Membrane blots were incubated with antibodies
gainst SERCA2a and phospholamban (ABR-Affinity
ioreagents, 1:400 dilution, Golden, Colorado) overnight at
oC. Reactive bands were visualized by chemiluminescence
PE Life Sciences, Inc., St. Petersburg, Florida), and films
rom at least 3 independent experiments were scanned and
ensities of the immunoreactive bands were evaluated using
IH Image software. Protein levels of glyceraldehyde
-phosphate dehydrogenase (GAPDH) were used as internal
ontrol. Density values of bands of SERCA2a and phospho-
amban were normalized against GAPDH values.
NA isolation and reverse transcription-polymerase
hain reaction (RT-PCR). The mRNA levels of
ERCA2a were measured using RT-PCR. Total RNA
as isolated using TRIzol reagent (Invitrogen) and by
dding chloroform after tissue disruption. After centrif-
gation, the RNA in the supernatant solution was pre-
ipitated by adding an equal volume of ice-cold isopro-
manol. RNA pellets were obtained by centrifugation at
2,000 g for 10 min at 4°C and washed by 75% ethanol.
ellets were resuspended in RNase-free water (Invitro-
en). The cDNA was synthesized from 1 g of total
NA using iScript reverse transcriptase (Bio-Rad Labo-
atories, Hercules, California) in a final volume of 20 l.
APDH mRNA levels served as internal controls. The
nnealing temperature for PCR reaction cycles was ad-
usted for each specific primer set. Density values of
ands of interest from 3 independent experiments were
ormalized against GAPDH values.
tatistical analysis. Continuous variables were reported
s mean  standard deviation. The 2-sided paired
tudent t test was used to analyze differences within the
ame group whereas the unpaired t test, for between-
roup differences. A p value 0.05 was considered
tatistically significant.
esults
total of 26 female Yorkshire-Landrace swine were subjected
o MR creation. Throughout the study, no significant differ-
nce in body weight was documented between study groups.
t 2 months, the 16 surviving swine were injected either with
AAV1.SERCA2a (n  10, group 1) or Saline (n  6, group
). Three animals died after virus injection: 1 was due to a
ost-catheterization stroke-like syndrome; another presented a
ersistent febrile state with deteriorating general status, and,
astly, 1 expired from worsening HF. Thirteen animals (n 7
rom group 1; n  6 from group 2) survived to 4 months.
ardiac function and remodeling. This severe MR model
esulted in a compensated state of HF as shown by the
bsence of overt systolic dysfunction in both groups (Table 1).
o significant difference was documented between the saline
nd SERCA2a groups for the following parameters: heart rate
2 months: 94  26 beats/min vs. 83  10 beats/min, 4
onths: 88  13 beats/min vs. 86  17 beats/min, respec-
ively; pNS), peak LV pressure (2 months: 94.9 24.0 mm
g vs. 92.4  8.0 mm Hg, 4 months: 103.4  14.8 mm Hg
s. 100.6  16.8 mm Hg, respectively; p  NS), and
nd-diastolic pressure (2 months: 10.9 5.5 mm Hg vs. 9.7
.5 mm Hg, 4 months: 14.0 1.2 mm Hg vs. 13.9 8.4 mm
g, respectively; p  NS). A significant difference was
ocumented between the saline and SERCA2a groups for
VEF Over Time Between Study Groups
Table 1 LVEF Over Time Between Study Groups
LVEF
Saline Group
(%, Mean  SD)
(n  6)
SERCA2a Group
(%, Mean  SD)
(n  7)
Before MR creation 57.5 9.6 58.4 8.3
At 2 months 64.4 9.6 64.7 7.4
At 4 months* 61.5 7.4 70.6 3.5
p  0.02, saline group versus sarcoplasmic reticulum Ca2 ATPase (SERCA2a) group at 4
onths.
LVEF  left ventricular ejection fraction; MR  mitral valve regurgitation.
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March 18, 2008:1112–9 SERCA2a Gene Transfer in HFVEF (61.5  7.4% vs. 70.6  3.5%, respectively; p  0.05)
Table 1), (dP/dt)max (1,396 383 mm vs. 1,822 317 mm
g/s, respectively; p  0.05), and adjusted rate of rise,
dP/dt)max/P (15.5 3.0 s1 vs. 21.2 3.2 s1, respectively;
 0.01) (Fig. 1).
Diastolic function was also evaluated after MR creation.
oth groups had comparable Tau values from at 2 months.
owever, after injection, a trend favoring the SERCA2a
roup was found with isovolumic relaxation abnormali-
ies progressing in the saline group in contrast to the
ERCA2a group (Fig. 2).
Figure 1 Differences in Adjusted Peak LV Pressure Rate of
Rise
Relative to the saline group, study animals that underwent gene transfer with
recombinant adeno-associated virus type 1 (rAAV1) sarcoplasmic reticulum
Ca2 ATPase (SERCA2a) had: 1) comparable peak left ventricular pressure rate
(dP/dt)max/P at the 2-month time point (state of compensated volume-over-
load heart failure); and 2) significant improvement in (dP/dt)max/P. This con-
firms a positive effect on left ventricular (LV) inotropy of SERCA2a
overexpression.
Figure 2 Differences in Time Constant of Isovolumic
Relaxation
Both study groups had no discernable difference in diastolic function at the
time of gene transfer. Over the course of the next 2 months after gene trans-
fer, there was a clear trend favoring the SERCA2a group for lack of deteriora-
tion of diastolic function. This confirms a potential positive effect on LV
lusitropy of SERCA2a overexpression. Tau  time constant of isovolumic relax-
ation; other abbreviations as in Figure 1.At 2 months, the volume-overload HF model was suc-
essful in inducing significant changes in ventricular param-
ters LVIDd as well as LVIDs compatible with remodeling
n both groups (Table 2). Moreover, when looking at the
rogression of ventricular dimensions over time (indirect
vidence of ventricular remodeling), there was significant
ifference between study groups favoring the SERCA2a
roup (Fig. 3).
Of note, no difference in MR regurgitant volume, as
easured by PISA method, was noted in both groups at the
ime of injection (47.9 26.4 ml, saline group vs. 52.3 21.8
l, SERCA2a group; p  NS). At follow-up, the values for
he regurgitant volume in the saline group at 2 months and 4
onths, respectively, were 47.9  26.4 ml to 62.4  35.6 ml,
nd in the SERCA2a group 52.3 21.8 ml to 47.9 25.8 ml.
he difference between 2 months and 4 months in terms of the
V Diameters After rAAV1.SERCA2a Gene Transfer
Table 2 LV Diameters After rAAV1.SERCA2a Gene Transfer
LV Diameters
Saline Group
(n  6)
SERCA2a
Group
(n  7)
LV internal diastolic diameter
(mm) (mean  SD)
Before MR creation 45.0 3.0 43.0 4.0
At 2 months 56.0 5.0 55.0 3.0
At 4 months 63.0 6.0 57.0 7.0
LV internal systolic diameter
(mm) (mean  SD)
Before MR creation 32.0 5.0 31.0 5.0
At 2 months 37.0 7.0 38.0 2.0
At 4 months* 42.0 6.0 34.0 4.0
p  0.02, saline group versus SERCA2a group at 4 months.
LV left ventricular; rAAV1 recombinant adeno-associated virus type 1; other abbreviations as
n Table 1.
Figure 3 LV Internal Systolic Diameters at 4 Months
Despite comparable diameters at baseline and at the time of gene transfer,
the saline group showed evidence of progression of their LV internal systolic
diameters at the term of the study. Conversely, animals that underwent
rAAV1.SERCA2a gene transfer were documented with persistent, stable LV
internal systolic diameters. This confirms a positive effect on LV remodeling of
SERCA2a overexpression. Abbreviations as in Figure 1.
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SERCA2a Gene Transfer in HF March 18, 2008:1112–9egurgitant fraction in the saline group was 22.1  30.2
hile in the SERCA2a group it was 4.4  16.3 (p  0.1).
ardiac tissue expression of SERCA2a and phospho-
amban. Cardiac tissue expression of SERCA2a was sig-
ificantly decreased in the saline group relative to the
ormal heart group. Conversely, SERCA2a expression
evels were restored to normal levels in the SERCA2a group
Fig. 4A). Further, despite a lack of difference in SERCA2a
RNA levels between the saline group and normal heart
roup, mRNA levels were significantly higher in the
ERCA2a group when compared with levels seen in
ither the saline group or the normal heart group (Fig.
B). Finally, the relative protein expression of phospho-
amban was comparable among the different groups as
hown in Figure 5.
dditional assessments. Adjusting for body weight, the
ERCA2a group had significantly smaller total LV muscle
ass (3.0  0.4 mg/kg vs. 3.6  0.4 mg/kg, respectively; p
0.05) and smaller total right ventricular muscle mass (0.9
0.1 vs.1.1 0.1 mg/kg, respectively; p 0.01) relative to
aline group. In collected cardiac tissue samples, no evidence of
istological changes compatible with acute myocardial toxicity
inflammation response, myocarditis, or vasculitis) related to
AAV1.SERCA2a gene transfer was documented. In addi-
ion, histological analyses did not reveal any direct evidence of
oxicity after gene transfer to other end-organs (results not
hown). Despite a wide range of total creatine kinase (CK)
evels (between 293 to 1,469 U/l), none of the CK-MB
Figure 4 SERCA2a Overexpression After Gene Transfer With rA
After gene transfer with the cardiotropic viral vector, rAAV1, both protein expressio
vated when compared with SERCA2a tissue expression in the saline group. This c
months after gene transfer) of the calcium cycling protein, SERCA2a. Control  no
failure; other abbreviations as in Figure 1.ractions reached significant levels in both groups.The rAAV1.SERCA2a gene transfer did not adversely
ffect hematologic parameters. No reticulocytosis or white
lood cell count increases (including eosinophils) were
ocumented nor were there increases in fibrinogen levels in
he SERCA2a group. Further, at 4 months, no altered renal
electrolytes, creatinine, blood-urea-nitrogen) and hepatic
Vector
ls (A) as well as mRNA levels (B) of SERCA2a were found to be significantly ele-
the ability of this viral vector to promote the persistent overexpression (2
eart group; GAPDH  glyceraldehyde 3-phosphate dehydrogenase; HF  heart
Figure 5 PLB Expression After Gene Transfer
With rAAV1 Vector
After gene transfer with the cardiotropic viral vector, recombinant adeno-
associated virus serotype 1 (rAAV1), protein expression levels of phospholam-
ban were found to be unchanged between groups. PLB  phospholamban;
other abbreviations as in Figures 1 and 4.AV1
n leve
onfirms
rmal h
(
a
(
r
A
c
4
w
g
r
f
s
(
t
D
A
c
i
n
E
c
s
o
s
a
(
l
g
t
S
p
f
r
b
h
f
s
o
a
e
a
p
n
v
p
d
(
i
d
s
i
p
e
n
r
g
h
fl
u
l
h
C
t
c
i
p
t
d
r
m
d
a
l
fl
t
e
e
a
t
r
g
c
i
1117JACC Vol. 51, No. 11, 2008 Kawase et al.
March 18, 2008:1112–9 SERCA2a Gene Transfer in HFaspartate amino transferase, alanine amino transferase,
lkaline phosphatase, total bilirubin) functions were found
results not shown). Finally, serial evaluations of BNP
evealed comparable levels between study groups at baseline.
t the time of sacrifice, the saline group showed a signifi-
ant increase in BNP levels relative to baseline (12,664 
,336 pg/ml vs. 5,704  962 pg/ml, respectively; p  0.05)
hereas such a difference was not noted in the SERCA2a
roup (7,472  1,456 pg/ml vs. 4,970  2,509 pg/ml,
espectively; p  NS). Moreover, there was a distinct trend
avoring the SERCA2a group at 4 months relative to the
aline group, with regard to deterioration of BNP levels
7,472  1,456 pg/ml vs. 12,664  4,336 pg/ml, respec-
ively; p  0.051) (Fig. 6).
iscussion
t the molecular and cellular level, disturbances in excitation-
ontraction coupling characterize the underlying defects relat-
ng to contractile function seen in HF (17). A pivotal compo-
ent of calcium handling is the SERCA2a pump (17–20).
arly experiments have shown that chemically induced de-
reased levels of SERCA2a could be improved (21) as well as
hortening and calcium transients by adenoviral gene transfer
f SERCA2a (8). Prior short-term, small-animal studies have
hown that gene transfer, to restore SERCA2a expression and
ctivity, can lead to functional improvement in failing hearts
9,10). Our study extends these results by showing that
ong-term overexpression of SERCA2a by in vivo rAAV1
ene transfer can positively impact cardiac function and struc-
ure in a large-animal model of HF.
ERCA2a expression using rAAV1. Reduced SERCA2a
Figure 6 Differences in BNP Levels Between Study Groups
At the time of rAAV1.SERCA2a gene transfer, all study animals had comparable
levels of brain natriuretic peptide (BNP) levels. The latter were significantly ele-
vated relative to baseline, evidence of a compensated state of volume-overload
heart failure. At the term of the study, 2 months after gene transfer, the pro-
gressive rise in BNP levels seen in the saline group was not seen in the
SERCA2a group. This confirms that SERCA2a overexpression could favor the
stabilization of the physiological effects resulting from volume-overload heart
failure. Abbreviations as in Figure 1.rotein levels and activity have been reported to occur in aailing hearts (5,7). Prior reports have shown the successful
estoration of the SERCA2a pump levels with a catheter-
ased technique in a small-animal model of HF with
omogenous expression patterns obtained after gene trans-
er by adenoviral vector (22). However, the latter vector
ystem only allows for transient transgene expression (on the
rder of days to weeks) (23). In an effort to favor clinical
pplicability and effectively target chronic progressive dis-
ase states (such as HF), more efficient vector systems
ssociated with long-term transgene expression are required.
Adeno-associated viruses are replication-defective, non-
athogenic parvoviruses with a single-stranded DNA ge-
ome (24,25). These viruses are emerging as promising
ectors, exhibiting serotype-specific tissue or cell-type tro-
ism, increased in vivo transduction efficiency to both
ividing and nondividing target cells, sustained expression
from several months to years), and reduced immunogenic-
ty compared with other viral vector systems (12,26). With
ocumented greater tissue-specific tropism for certain AAV
erotypes, transition towards clinical applicability is increas-
ngly feasible; AAV serotype 1 offers attractive biological
rofiles, such as muscle tropism and ability to bypass pre-
xisting immunity (i.e., neutralizing antibodies) due to
atural infection (27,28). Concerns of adverse immunologic
esponse from prior experience with adenoviral-mediated
ene delivery do not seem to apply to rAAV1 since our
istological specimens did not reveal any evidence of in-
ammatory reaction. In this study, we have thus shown that,
sing the rAAV1 vector, SERCA2a mRNA and protein
evels can be successfully and safely overexpressed in swine
earts up to 2 months after delivery.
ardiac gene transfer. An important challenge to clinical
ranslation of pre-clinical findings has been the efficiency of
urrent myocardial gene transfer strategies (11). Direct
ntramyocardial viral vectors injection has been reported in
re-clinical studies. However, major technical drawbacks of
his approach remain: 1) a limited surface area of the myocar-
ium efficiently transfected; and 2) the surgical nature of this
oute would conceivably not represent the ideal strategy for the
ajority of HF patients.
Intracoronary delivery remains an attractive alternative
ue to its limited invasiveness as well as for the possibility to
ttain widespread myocardial gene delivery. Initial studies in
arge-animal models using adenovirus have reported con-
icting results in terms of consistency of transfection rates of
his delivery strategy (29,30). Potential hurdles hampering
fficient viral vector transfection are size and type of vector
mployed, vehicle composition, coronary flow and pressure,
nd time of exposure of the vector to the coronary endo-
helium (31). Our group has previously reported on the
eproducibility, feasibility, and safety of percutaneous ante-
rade myocardial adenoviral gene transfer with concomitant
oronary venous blockade in swine hearts (32).
In this study, to simplify the process of intracoronary
njection and to test the myocardial transfection efficiency ofdifferent, more cardiotropic viral vector, we chose slow,
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SERCA2a Gene Transfer in HF March 18, 2008:1112–9elective left coronary artery rAAV1.SERCA2a delivery.
his approach not only resulted in successful transfection
increased SERCA2a protein and mRNA levels), but, more
mportantly, in documented improvement in functional and
hysiological parameters.
ffect of SERCA2a on cardiac function and struc-
ure. Results from transgenic animals (33) as well as small-
nimal studies have convincingly shown enhancement of
ontractility resulting from overexpression of SERCA2a.
ith respect to disturbances of Ca2 handling, the need to
etter define gene transfer in large-animal models is under-
cored by known discrepancies between species. Whereas in
ats 90% of cytosolic Ca2 is handled by the SERCA2a
ump, in human hearts, the latter’s contribution falls to 75%
ith the remainder of cytosolic Ca2 being managed by the
a/Ca2 exchanger (20). Further, surprising findings of
uman dilated cardiomyopathy caused by mutation leading
o reduced expression of phospholamban, a direct inhibitor
f SERCA2a activity, stands in stark contrast to pre-clinical
eports (34). Translational research thus represents not just
 logical but necessary step before clinical application.
Bearing in mind known limitations of LVEF as a reliable
stimate of systolic function in the setting of severe MR, we
elieve that our HF model is physiologically relevant in that
tudy groups were most likely in a compensated state of
ilated cardiomyopathy. This state represents a commonly
ccurring, clinically pertinent scenario with increasing num-
ers of compensated HF patients due to advances in both
edical and device therapies. In light of this, the present
tudy represents, to our knowledge, the first report docu-
enting that gene transfer (with rAAV1.SERCA2a vector)
ignificantly impacted on parameters of inotropy, showed a
avorable trend for lusitropy, and improved remodeling in
he setting of a large-animal model of progressive HF.
tudy limitations. An important drawback of this study is
he small number of study animals. Though associated with
igh mortality, this physiologically relevant large-animal
odel of HF allowed us to show discernable differences (for
xample, in systolic function and ventricular parameters of
emodeling) or trends towards significance (such as was the
ase for diastolic dysfunction) between study groups. In
ddition, in our model of MR, Tau as one of the indexes of
iastolic dysfunction may be hard to interpret. Greater
umber of surviving animals would have probably provided
ore robust statistical comparisons. Moreover, a more
xtended period of follow-up after gene transfer might have
een more insightful for the progression of the HF model
nd to better contrast the positive effects of SERCA2a
verexpression relative to the saline group. The potential
ro-arrhythmic effect of SERCA2a gene transfer remains
ontroversial (35,36). While we did not monitor for arrhyth-
ias with continuous loop-recordings or Holter monitors, no
ocumented deaths after gene transfer were sudden. In
ontrast to previous reports in pre-clinical studies, 2
onths after SERCA2a transfection, there was no evi-
1ence of sudden death or clinically significant ventricular
rrhythmias.
linical implications. The delivery methodologies we de-
cribe in this study can be directly transferred to the clinical
etting in patients. Since issues with biodistribution and
afety profiles of rAAV1.SERCA2a have been resolved,
ene therapy trials with rAAV1.SERCA2a have begun.
onclusions
n a volume-overload model of HF, long-term overexpres-
ion of SERCA2a by in vivo AAV1-mediated gene transfer
via intracoronary delivery) can preserve systolic function,
otentially prevent diastolic dysfunction, and improve ven-
ricular remodeling. These encouraging results pave the way
or further studies to better define safety and feasibility of
his promising therapeutic approach to HF.
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